tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Leah Rush Cann, 136 are a BUY (97.84%), 3 are a HOLD (2.16%).
Analyst Leah Rush Cann, currently employed at BROOKLINE, carries an average stock price target met ratio of 45.91% that have a potential upside of 40.14% achieved within 369 days. Previously, Leah Rush Cann worked at OPPENHEIMER, CANACCORD.
Leah Rush Cann’s has documented 288 price targets and ratings displayed on 24 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on KYMR, Kymera Therapeutics at 08-Jun-2026.
Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 10-Jan-2025
$430
$-2.49 (-0.58%)
$435
Buy Since 26-Jan-2026
$470
$37.51 (8.67%)
$430
Hold Since 12-Oct-2026
$415
$-17.49 (-4.04%)
$450
Buy Since 05-Aug-2026
$430
$-2.49 (-0.58%)
$400
9 days ago
(08-Oct-2026)
3/3 (100%)
$22.56 (5.54%)
48
Hold Since 07-Oct-2024
$440
$7.51 (1.74%)
$400
9 days ago
(08-Oct-2026)
31/36 (86.11%)
$32.56 (7.99%)
316
Which stock is Leah Rush Cann most bullish on?
What Year was the first public recommendation made by Leah Rush Cann?
